Prognostic value of bcl‐6, CD10 and CD38 immunoreactivity in stage I–II gastric lymphomas: Identification of a subset of CD10+ large B‐cell lymphomas with a favorable outcome

Open Access
Publisher Website
Google Scholar
Abstract
Bcl‐6, CD10 and CD38 are useful markers for identifying 2 molecularly and prognostically distinct profiles of diffuse large B‐cell lymphomas (LCLs), defined as germinal‐center B‐like and activated B‐like. We investigated the prognostic role of bcl‐6, CD10 and CD38 immunoreactivity in 102 gastrectomized patients with primary gastric lymphomas (PGLs). There were 41 low‐grade marginal zone lymphomas of MALT‐type (LGML) and 61 diffuse large B‐cell lymphomas with (DLCLMLs; n = 31) or without (DLCLs; n = 30) an LGML component. bcl‐6, CD10 and CD38 were significantly more commonly expressed in DLCL or DLCML as compared with LGML (50% vs. 48% vs. 17%, p = 0.0002 for bcl‐6; 27% vs. 26% vs. 0%, p = 0.0004 for CD10; 45% vs. 48% vs. 13%, p = 0.0005 for CD38, respectively). CD10 immunoreactivity was independently associated with a better survival in diffuse LCL patients (5‐year overall survival: 88% ± 8% vs. 66% ± 7%; p = 0.04); bcl‐6 or CD38 immunoreactivities did not disclose any prognostic implication. Age, presence of LGML component, lactic dehydrogenase serum levels and use of chemotherapy were additional independent prognostic factors. We conclude that CD10 immunoreactivity assessment could be a clear, easy‐to‐interpret and reliable prognostic factor in PGL. Accordingly, patients with CD10+ gastric large B‐cell lymphomas may be at reduced risk and eligible for clinical trials evaluating more conservative therapeutic options.